Processa Pharmaceuticals, Inc.
PCSA
$2.55
-$0.01-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.59M | 1.83M | 1.50M | 1.26M | 1.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.70M | 3.49M | 3.95M | 2.85M | 2.73M |
| Operating Income | -3.70M | -3.49M | -3.95M | -2.85M | -2.73M |
| Income Before Tax | -3.36M | -3.44M | -3.93M | -2.83M | -2.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.36M | -3.44M | -3.93M | -2.83M | -2.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.36M | -3.44M | -3.93M | -2.83M | -2.73M |
| EBIT | -3.70M | -3.49M | -3.95M | -2.85M | -2.73M |
| EBITDA | -3.70M | -3.49M | -3.95M | -2.85M | -2.73M |
| EPS Basic | -1.49 | -1.81 | -6.32 | -7.44 | -19.41 |
| Normalized Basic EPS | -0.93 | -1.13 | -3.95 | -4.65 | -12.13 |
| EPS Diluted | -1.49 | -1.81 | -6.32 | -7.44 | -19.41 |
| Normalized Diluted EPS | -0.93 | -1.13 | -3.95 | -4.65 | -12.13 |
| Average Basic Shares Outstanding | 2.26M | 1.90M | 622.80K | 381.10K | 140.60K |
| Average Diluted Shares Outstanding | 2.26M | 1.90M | 622.80K | 381.10K | 140.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |